Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $41.20 Consensus Target Price from Brokerages

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has been given a consensus recommendation of “Moderate Buy” by the six brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $41.20.

ELVN has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th.

Insiders Place Their Bets

In other news, CEO Samuel Kintz sold 12,500 shares of the business’s stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $21.33, for a total value of $266,625.00. Following the completion of the sale, the chief executive officer directly owned 902,892 shares in the company, valued at approximately $19,258,686.36. The trade was a 1.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Anish Patel sold 6,667 shares of the company’s stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $20.10, for a total transaction of $134,006.70. Following the completion of the sale, the chief operating officer directly owned 276,641 shares of the company’s stock, valued at $5,560,484.10. This trade represents a 2.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 89,001 shares of company stock valued at $1,826,456. 25.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Commodore Capital LP lifted its stake in shares of Enliven Therapeutics by 0.4% in the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock valued at $94,138,000 after acquiring an additional 17,809 shares during the last quarter. Polar Capital Holdings Plc lifted its position in Enliven Therapeutics by 1.5% in the third quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company’s stock valued at $63,355,000 after purchasing an additional 44,713 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Enliven Therapeutics by 5.9% during the third quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock valued at $52,260,000 after purchasing an additional 142,378 shares during the period. Vestal Point Capital LP boosted its stake in shares of Enliven Therapeutics by 364.0% during the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock valued at $23,745,000 after purchasing an additional 910,000 shares during the period. Finally, Duquesne Family Office LLC grew its holdings in shares of Enliven Therapeutics by 104.6% in the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after purchasing an additional 484,405 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock opened at $22.10 on Thursday. Enliven Therapeutics has a 1 year low of $13.30 and a 1 year high of $26.48. The firm has a market cap of $1.31 billion, a PE ratio of -12.01 and a beta of 0.80. The company has a 50 day simple moving average of $20.38 and a two-hundred day simple moving average of $20.13.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.11. As a group, research analysts anticipate that Enliven Therapeutics will post -1.95 earnings per share for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.